Clinical Trials

32 enrolled

Clinical Stage 0 Gastric Cancer AJCC v8

NCT04481204 2026-04-15

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

105 enrolled

Borderline Resectable Pancreatic Adenocarcinoma

NCT06417476 2026-04-13

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

66 enrolled

Rectal Neoplasms

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT03764553 2026-04-07

LyRICX

320 enrolled

Esophageal Neoplasms

NCT04245865 2026-04-03

Toco-CoR

83 enrolled

Colorectal Neoplasms

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Phase EARLY_PHASE1 Active not recruiting

40 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

2 enrolled

Colonic Neoplasms

NCT01918527 2026-03-10

Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer

250 enrolled

Phase 1 Active not recruiting

Colonic Neoplasms

NCT04522336 2026-03-05

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

16 enrolled

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

NCT04757363 2026-03-04

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

39 enrolled

Esophageal Neoplasms

NCT04094688 2026-03-03

SOLARIS

455 enrolled 13 charts

Phase 1 Active not recruiting

Colorectal Adenocarcinoma

NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

38 enrolled

Neoplasms

NCT05171660 2026-02-17

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

446 enrolled

Colorectal Neoplasms

NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

30 enrolled

Advanced Biliary Tract Carcinoma

NCT04340141 2026-02-10

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

358 enrolled

Pancreatic Neoplasms

NCT06268015 2026-02-05

BBOpCo

16 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

80 enrolled

Adenocarcinoma

NCT03399110 2026-01-27

XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)

1,024 enrolled

Phase 2/3 Active not recruiting

Stomach Neoplasms

NCT04137107 2026-01-26

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

220 enrolled

Phase 2/3 Active not recruiting

Colorectal Neoplasms

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

580 enrolled

Adenocarcinoma

NCT05026905 2026-01-20

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

66 enrolled

Pancreatic Neoplasms

NCT00335816 2026-01-14

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

248 enrolled

Rectal Neoplasms, Colorectal Neoplasms

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

42 enrolled 13 charts

Pancreatic Adenocarcinoma

NCT05504252 2026-01-07

METIMMOX-2

80 enrolled

Adenocarcinoma, Mucinous, Carcinoma, Signet Ring Cell

NCT05627635 2025-11-10

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

20 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

120 enrolled

Pancreatic Neoplasms

NCT06124378 2025-09-24

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

60 enrolled

Phase 1 Active not recruiting

Colonic Neoplasms

NCT01061515 2025-09-17

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

21 enrolled

Carcinoma

NCT03110926 2025-09-12

Induction Chemotherapy for Locally Advanced Esophageal Cancer

40 enrolled

Esophageal Neoplasms

NCT05610163 2025-09-08

JANUS

783 enrolled

Rectal Neoplasms

NCT02008656 2025-08-27

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

358 enrolled

Rectal Neoplasms

NCT00492999 2025-08-17

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

64 enrolled

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT03493048 2025-08-03

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

146 enrolled

Colorectal Neoplasms

NCT07090031 2025-07-29

Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer

49 enrolled

EFS

NCT03421288 2025-07-25

DANTE

677 enrolled

Stomach Neoplasms

NCT04594772 2025-07-02

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

32 enrolled

Pancreatic Neoplasms

NCT05253846 2025-06-10

ShorTrip

63 enrolled

Locally Advanced Rectal Cancer

NCT03448835 2025-06-08

PANDA

20 enrolled

Stomach Neoplasms

NCT04043195 2025-05-28

NSCLC

Phase 2/3 Active not recruiting

30 enrolled

Thoracic

Advanced NSCLC

NCT04068103 2025-05-07

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

635 enrolled 9 charts

Colonic Neoplasms

NCT04251715 2025-04-18

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

5 enrolled

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT02572141 2025-03-19

OPTICAL

738 enrolled

Colonic Neoplasms

NCT02980510 2025-02-20

PANIRINOX

219 enrolled

Colorectal Neoplasms

NCT03255434 2025-02-13

LEANOX

160 enrolled

Colonic Neoplasms

NCT06766019 2025-01-09

Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer

47 enrolled

Pancreatic Neoplasms

NCT05121038 2024-12-17

CENDIFOX

50 enrolled

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT01531595 2024-12-12

AXOAXI

100 enrolled

Colorectal Neoplasms

NCT04940546 2024-12-03

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

36 enrolled